Late-Breaking Advances, Epidemiology, and Evolving Challenges on the Therapeutic Landscape for Stroke Prevention in Atrial Fibrillation (SPAF) Christian T. Ruff, MD, MPH
State-of-the-Art Risk Stratification of Patients with Atrial Fibrillation: Anticoagulation Strategies Based on Established and Evolving AF Scoring Systems for Thrombosis and Hemorrhagic Risk Jonathan L. Halperin, MD
From Risk to Remedy: Deciphering the Maze of Evidence from Landmark Trials Evaluating Non-Monitored, Oral Anticoagulants (NMOACs) for SPAF Alexander G. G. Turpie, MD, FRCP, FACP, FACC, FRCPC
Clinical Dilemmas and Decision-Making in Patients Requiring SPAF: Aligning Appropriate Therapies in Moderate and High Risk Groups with AF—What Does the Cardiologist’s Clinical Decision Tree for SPAF Currently Look Like? Samuel Z. Goldhaber, MD - Program Chairman
Question and Answer Faculty Panel
Chairman Conclusion Samuel Z. Goldhaber, MD - Program Chairman
